Abstract:OBJECTIVE:To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) that have assessed the effect and safety of ursodeoxycholic acid (UDCA), S-adenosylmethionine (SAMe) and UDCA-SAMe combination therapies for intrahepatic cholestasis of pregnancy (ICP).METHODS:Using searching protocols and assessment methods recommended by the Cochrane Collaboration to reduce bias in systematic reviews, the databases of Medline, EMBASE, Cochrane Central Register of Controlled Trials (CCRT), China National Knowledge Infrastructure (CNKI), Chinese BioMedical Literature (CBM) and Wanfang China Online Journals were searched to identify relevant RCTs published from database inception to December 2011.RESULTS:Ten RCTs (of 727 pregnant women) were included in the study and represented a low risk for bias. Compared to the patients who received UDCA monotherapy, those who received UDCA-SAMe combination therapy had significantly lower rates of Cesarean section (odds ratio (OR) =0.45, 95% confidence interval (CI):0.24-0.86), preterm birth (OR=0.36, 95% CI:0.20-0.63), and fetal asphyxia (OR=0.27, 95% CI:0.13-0.56) (all P less than 0.05); however, the UDCA-SAMe therapy did not provide better rates of amniotic fluid pollution (OR=0.38, 95% CI:0.14-1.01) or better new bom weight (mean difference (MD) =397.36, 95% CI:-96.17-890.89). Compared to the patients who received SAMe monotherapy, those who received UDCA-SAMe combination therapy had significantly lower rates of preterm birth (OR=0.39, 95% CI:0.21-0.73), fetal asphyxia (OR=0.23, 95% CI:0.07-0.75), and amniotic fluid pollution (OR=0.41, 95% CI:0.20-0.85) (all, P less than 0.05); however, the UDCA-SAMe therapy did not provide better rates of Cesarean section (OR =0.62, 95% CI:0.27-1.44) or better new bom weight (MD =445.95, 95% CI:-143.51-1035.42). Comparison of the two monotherapies (UCDA vs.SAMe) showed no statistical differences in rates of Cesarean section (OR=0.91, 95% CI:0.47-1.78), preterm birth (OR =0.79, 95% CI:0.49-1.38), fetal asphyxia (OR=0.90, 95% CI:0.38-2.12), and amniotic fluid pollution (OR=1.14, 95% CI:0.61-2.13), as well as of new born weight (MD =-62.86, 95% CI:-157.81-32.09). Six studies reported no side effects.None of the included studies reported use of allocation concealment or blinding.CONCLUSION:UDCA-SAMe combination therapy is better than either UDCA or SAMe monotherapy for improving the outcome of ICP without adverse effects. Large-scale trials with adequate sample sizes and higher quality study design are needed to further confirm the efficiency and safety of UDCA and SAMe for treating ICP.

Effects of Ursodeoxycholic Acid on Hepatic Na+-K+-ATPase, Hepatic Function, and Pathohistology in Pregnant Rats with 17-Α-ethinylestradiol and Progesterone Induced Intrahepatic Cholestasis

[Effects of Ursodeoxycholic Acid on the Liver Plasma Membrane Fluidity, Hepatic Glutathione Concentration, Hepatic Estrogen Receptors and Progesterone Receptors in Pregnant Rats with Ethinylestradiol and Progesterone Induced Intrahepatic Cholestasis].

Effects of Ursodeoxycholic Acid on Intrahepatic Cholestasis in Rats

Effect of compound ursodeoxycholic acid oral liquid on cholestatic hepatitis in rats

Treatment Of Intrahepatic Cholestasis Of Pregnancy Using Ursodeoxycholic Acid: A Meta-Analysis

Effect of ursodeoxycholic acid and olynicate and naphthylactic acid on chronic hepatitis B and intrahepatic cholestasis

Perinatal Outcomes Of Ursodeoxycholic Acid Treatment In Twin Pregnancies With Intrahepatic Cholestasis: A Five-Year Retrospective Cohort Study

Ursodeoxycholic Acid and S-adenosylmethionine for the Treatment of Intrahepatic Cholestasis of Pregnancy: A Meta-analysis.

Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: Effects on primary bile acids in babies and mothers

The Clinical study on therapy of chronic hepatitis B with severe cholestasis applied by ursodeoxycholic Acid

Efficacy of Ursodeoxycholic Acid in Treatment of High Level Glycocholic Acid During Pregnancy

UDCA Prevents 17α‐Ethinylestradiol‐induced Cholestatic Injury via Inhibiting AMP‐activated Protein Kinase Activation

The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

Ursodeoxycholic acid for nonalcoholic steatohepatitis.

Effect of Ursodeoxycholi acid on liver cirrhosis with hepatitis B

Obeticholic Acid Protects against Gestational Cholestasis-Induced Fetal Intrauterine Growth Restriction in Mice

[Effect of Integrative Chinese and Western Medicine in Treating Pregnant Women with Intrahepatic Cholestasis].

[Influence of Ursodeoxycholic Acid on the Therapeutic Effects of Low-Calorie Diet in Obesity and Hyperlipidemia Rats with Steatohepatitis].

[Meta-Analysis of Ursodeoxycholic Acid and S-adenosylmethionine for Improving the Outcomes of Intrahepatic Cholestasis of Pregnancy].

UDCA and CDCA Alleviate 17Α-Ethinylestradiol-induced Cholestasis Through PKA-AMPK Pathways in Rats.